Physician profile
Barbara Wilhelm
NPI 1154385565
$8,163.50
in general payments reported to CMS, 2019-2025
30 companies · $849 in 2025
The $849 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,241 · 2020: $1,158 · 2021: $1,184 · 2022: $1,166 · 2023: $1,345 · 2024: $1,220 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,414.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $944.37 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $790.27 | 2019-2023 | Xarelto |
| Abbvie INC. | $751.48 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $731.51 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $708.70 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $675.81 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $661.69 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $436.10 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $366.63 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $217.04 | 2019-2021 | |
| Astellas Pharma US INC | $213.26 | 2019-2021 | |
| Abbott Laboratories | $186.03 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| E.R. Squibb & Sons, L.L.C. | $159.78 | 2019-2023 | Eliquis |
| Amgen INC. | $151.26 | 2021-2025 | Repatha, Otezla, Otezla |
| Otsuka America Pharmaceutical, INC. | $139.52 | 2024-2025 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $135.62 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.90 | 2019-2024 | Xifaxan, Trulance |
| Eisai INC. | $125.77 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $112.99 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $108.63 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $78.22 | 2022 | |
| Novartis Pharmaceuticals Corporation | $68.07 | 2019-2023 | |
| Exact Sciences Corporation | $67.67 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $50.13 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.44 | 2022-2025 | Caplyta |
| Arbor Pharmaceuticals, INC. | $27.63 | 2019-2020 | |
| Sanofi Pasteur INC. | $26.39 | 2022-2023 | |
| Biodelivery Sciences International, INC. | $25.43 | 2021 | |
| Neurocrine Biosciences, INC. | $17.76 | 2024 | Ingrezza |
| Daiichi Sankyo INC. | $15.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Wilhelm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.